
Starling Oncology fell 6.1% from $3.77 to $3.54, behind the S&P 500's +11.2%. Its worst day was Nov 6 (−46.0%), and its low came Feb 12 at $2.39.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Starling Oncology closed at its lowest level of the year, 36.7% below where the year started.
−9.0% · S&P 500 −1.5%
EPS of $-0.06 beat the $-0.09 estimate on $142.0M revenue (est. $140.3M).
Story events cover the past 12 months · Times ET
+8.4% · S&P 500 −0.6%
EPS of $-0.02 beat the $-0.08 estimate on $147.4M revenue (est. $142.6M).
−1.7% · S&P 500 +0.8%
EPS of $-0.08 missed the $-0.06 estimate on $161.3M revenue (est. $156.9M); FY revenue guidance of $650.0M–$670.0M against the $657.9M consensus.
+28.5%, the year's best day · S&P 500 +0.6%
Starling Oncology closed at its highest level of the year, 87.0% above where the year started.
+3.2% · S&P 500 0.0%
EPS of $-0.13 missed the $-0.05 estimate on $169.8M revenue (est. $168.6M); FY revenue guidance of $650.0M–$660.0M against the $665.0M consensus.
−46.0%, the year's worst day, on 24M shares, the year's heaviest volume · S&P 500 +0.3%
Where it ended: a close of $3.54 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.04, revenue est. $177.6M).
Nothing in the past 12 months.
All STLN dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for STLN and SPY from Benzinga historical bars. Not investment advice.